The Psychedelics Newsletter, Issue 112

Beckley Psytech’s study of 5-MeO-DMT and the acquisition of Eleusis

In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of UK-based Eleusis.

Analysts have predicted a surge of M&A activity in psychedelic healthcare, following a widespread industry shakeout accelerated by a turbulent economic climate.

To discuss the organisation’s clinical trials and investments, PSYCH spoke with Beckley Psytech’s CEO Cosmo Feilding Mellen.

READ MORE

THE RISE PSYCHEDELIC RESEARCH IN THE UK

The Psychedelics as Medicine Report revealed two-thirds of Europeans support the legalisation of psychedelic medicine.

READ MORE

QUEBEC REIMBURSES COST OF PSYCHEDELIC HEALTHCARE

The Canadian province has set a precedent by paying for patients to receive psychedelic-assisted therapy.

READ MORE

BUSINESS AND INVESTMENT

• Gilgamesh raises $39m in?Series B funding round.
• Small Pharma completes?Phase II DMT study.
• The training of therapists to?administer psychedelic medicine.
• Regulators are supporting psychedelic research?through expedited pathways.
• Filament Health to supply Psyence?for palliative care.
• Further research needed to justify the potential?of psychedelic medicine.
• Ketamine-assisted therapy shows promise for?alcohol-use disorder.
• Insurance companies increasingly cover?psychedelic-assisted therapy.

Following the success of the SOLD OUT PSYCH Symposium in 2022, the industry-leading conference returns to the iconic British Museum?on Thursday, 6 July 2023.

Super Early Bird tickets now on sale for ￡249 + VAT.

SCIENCE AND RESEARCH

• University College London to conduct DMT?brain imaging study.
• Challenges and gaps?in psychedelic research.
• The risks and rewards of psilocybin therapy?for bipolar disorder.
• Ketamine induces?neuronal cell development.
• How genetics determine response?to psychedelic medicine.
• University of Sydney researchers study psilocybin for?alcohol-use disorder.

Decision makers from across psychedelic healthcare converged at PSYCH Symposium: London 2022, to shape the future of psychedelic medicine.?

Over 45% of the attendees were C-Suite and senior management level, with the NHS, BBC, The Economist and University of Cambridge in attendance.

In this series of short interviews, industry thought leaders reveal why it was Europe’s premier psychedelic healthcare event.

REGULATION AND LEGISLATION

• National Police Chiefs’ Council?proposes decriminalisation measure.
• Decriminalisation bill?reintroduced in California.
• Oregon adopts final rules?for psilocybin services.
• An overview of?Breakthrough Therapy Designation.
• How the US streamlines?psychedelic drug development.
• US regulatory?reform in 2023.
• Ketamine therapy regulation?challenges in Colorado.
• The case for drug?reform in Massachusetts.?

The psychedelic healthcare industry is expected to be worth US$2.5b by 2025.

The Psychedelics as Medicine Report?provides market data and industry insights, with an exclusive contribution from Crispin Blunt MP, Chair of the Conservative Drug Policy Reform Group.

ARTICLES OF INTEREST

• UK parents call?for drug decriminalisation.
• The start of 1967’s?Summer of Love.